Recently (July 14), Roche announced that its CD20xCD3 T cell combined with dual-characteristic cancer immunotherapy mosunetuzumab has received FDA Breakthrough Therapy Designation (BTD). Dr. Levi Garraway, Roches Chief Medical Officer and He...

Last week, during the review process of GlaxoSmithKlines targeted BCMA-ADC (antibody-drug conjugate)---Belantamab mafodotin, FDA staff expressed concern about the ocular toxicity and side effects of the drug treatment, although Ge Lan Su Shi...

On July 15, 2020, San Diego BioAtla, Inc. (BioAtla) is a global clinical stage biotechnology company dedicated to the development of conditional activated biological (CAB) antibody therapies. It announced the completion of the D round of fin...